View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
Patients with type 2 diabetes who took a once-weekly formulation of exenatide in a clinical trial maintained better hemoglobin A1C and fasting plasma glucose levels than those who took the commonly prescribed formulation of the drug, which is administered twice a day. The long-acting release formulation combined exenatide with material used in resorbable sutures to prolong drug effects. Patients took the drug once a week, but the drug was released over weeks or months.
The study involved 295 patients with type 2 diabetes who received the drug either once a week or twice a day for 30 weeks. Levels of hemoglobin A1C decreased 1.9% in patients who took the weekly dose compared with 1.5% who took the drug twice daily. Fasting plasma glucose levels dropped by 42 mg/dL in those taking the weekly dose, compared with a drop of 25 mg/dL in those who took the drug twice daily. Patients also tolerated the once-weekly preparation better than the twice-daily one, which commonly causes nausea.
Known as an incretin mimetic, exenatide mimics the action of hormones that regulate blood glucose by stimulating glucose-dependent insulin secretion, inhibiting glucagon secretion, and slowing gastric emptying. Researchers presented the study at the American Diabetes Association 68th Scientific Sessions in San Francisco, Calif.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top